This data set comprises de-identified transcripts of semi structured qualitative interviews conducted as part of the ESRC funded project “Biomodifying technologies and experimental space: organisational and regulatory implications for the translation and valuation of health research”. The project was led by researchers based in the Centre for Health, Law and Emerging Technologies at the University of Oxford in partnership with colleagues at the Universities of Sussex and York. Biomodifying technologies are those which modify living biological tissue in novel and increasingly patient-orientated and customised ways. The case study biomodifying technologies in this project were: ‘gene-editing’ whose goal is to understand and remove disease-related mutations, the creation of induced pluripotent stem cells that can be controlled to create different types of tissue for cell therapy, and the emergence of 3D printing of biological material which aims to create novel structures for bodily repair and renewal. The project addressed the following research questions: 1) How can the experimental space which these technologies currently occupy be characterised? What impact will this have on translational health research and its likely trajectories? 2) What are the challenges and risks posed by these technologies for existing, legal, regulatory and governance regimes? How are development strategies being shaped by these regimes? 3) What is defined as the benefit or value of these technologies? Which groups benefit or are seen to benefit, and how is benefit and value assessed? How does consensus about their value build? The project team utilised a mixed methods approach for UK fieldwork combining documentary analysis of various literatures, including the academic and grey literatures, with qualitative semi-structured interviews with a range of key stakeholders in each of the fields being studied. These include scientists working in academic laboratories, representatives of SMEs, research agencies, regulators, and senior staff in important service organisations.

UK academic scientists, including clinical scientists, at multiple universities; representatives of Small-to Medium Sized UK biotechnology companies or biotechnology companies with operations in the UK; representatives of other companies associated with cell-and/or-gene based therapies or 3D bio-printing and medical 3D printing, usually in a service provision capacity to this industry, representatives of UK organisations (public and private) involved in the regulation and oversight of biomedical innovation, including but not limited to intellectual property rights (e.g. patent attorneys).